August 14, 2020

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

Category: Article Summary

Topic: Vaccines and Immunity

• Xia et al. report interim analyses of an ongoing randomized, double-blind, placebo-controlled phase 1 (n=96) and 2 (n=224) clinical trials of an inactivated whole-virus COVID-19 vaccine conducted in Henan Province, China. All participants who were randomized completed the trial up to 28 days post-vaccination. Frequency of adverse reactions increased with dose and the most common adverse reactions were injection site pain and fever, which were mild and self-limiting, with no serious adverse reactions noted. Immunogenicity was noted in all dose groups.  

Xia et al. (Aug 13, 2020). Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA. https://doi.org/10.1001/jama.2020.15543